BioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018

**Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250)**

SAN RAFAEL, Calif., Sept. 5, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present 20 poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018, which will be held on September 4-7 in Athens, Greece.

**Listing of Posters and Presentations at Society for the Study of Inborn Errors of Metabolism 2018 Symposium**

**Poster Presentations**

<table>
<thead>
<tr>
<th><strong>CLN2 Disease</strong></th>
<th><strong>Authors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring neuropsychological function in CLN2 disease</td>
<td>Nickel M, Augustine E, Adams H, Baron I, Bjoraker K, Cohen-Pfeffer J, Delaney K, Elmerskog B, Newsom-Davis I, Rust S, Shapiro E, Tøssebro A, Schulz A</td>
</tr>
<tr>
<td><strong>Poster: #345</strong></td>
<td></td>
</tr>
<tr>
<td>Experiences of CLN2 disease diagnosis in the UK</td>
<td>Burke D, Church H, Jackson M, Powers V, Tylee K</td>
</tr>
<tr>
<td><strong>Poster: #357</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #367</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Phenylketonuria (PKU)</strong></th>
<th><strong>Authors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster: #095</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #097</strong></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Phenylketonuria patients – a retrospective study of US health insurance claims data</td>
<td>I, Cohen-Pfeffer J, Irwin D, Levy H, Rohr</td>
</tr>
<tr>
<td><strong>Poster: #098</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #099</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #117</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #122</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #123</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #124</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #125</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Poster: #126</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Mucopolysaccharidosis (MPS)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Title</strong></td>
<td><strong>Authors</strong></td>
</tr>
<tr>
<td><strong>Poster: #315</strong></td>
<td></td>
</tr>
<tr>
<td>Poster</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>#316</td>
<td>Critical care situations in patients with mucopolysaccharidosis (MPS)</td>
</tr>
<tr>
<td>#362</td>
<td>Mucopolysaccharidosis VI enzyme replacement therapy outcomes across the disease spectrum: findings from the MPS VI clinical surveillance program</td>
</tr>
<tr>
<td>#364</td>
<td>Mucopolysaccharidosis VI enzyme replacement therapy initiated in adulthood: findings from the MPS VI clinical surveillance program</td>
</tr>
</tbody>
</table>

**About BioMarin**

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

**Contact:**

**Investors:**
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558

**Media:**
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451

SOURCE BioMarin Pharmaceutical Inc.